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OBJECTIVES The goal of this study was to determine the interaction between smoking and the glycoprotein
IIIa P1A2 polymorphism in patients admitted with non–ST-elevation acute coronary
syndromes (ACS).
BACKGROUND An increased incidence of the P1A2 polymorphism in smokers presenting with ST-elevation
acute myocardial infarction (AMI) has recently been reported. We, therefore, postulated that,
as a consequence of this interaction, fewer smokers with the P1A2 polymorphism would
present with non–ST-elevation ACS.
METHODS We performed a prospective cohort analysis of 220 white Caucasoid patients admitted with
non–ST-elevation ACS fulfilling Braunwald class IIIb criteria for unstable angina who were
stratified by smoking status.
RESULTS There were twice as many nonsmokers as smokers. Nonsmokers compared with smokers were
older (mean [SD]; 63.9 [11.2] vs. 57.6 [10.3]; p 0.0001), more likely to have had a previous
admission with unstable angina (24.3% vs. 13.2%; p  0.051) and AMI (45.8% vs. 30.3%;
p  0.026), more likely to have undergone revascularization (24.3% vs. 1.8%; p  0.028) and
were more likely to be on aspirin on admission (60.4% vs. 44.7%; p 0.026). The proportion
of nonsmokers positive for the P1A2 polymorphism was equivalent to that expected for this
population but was significantly reduced in smokers (28.7% vs. 10%; Pearson chi-square 
9.09, p  0.0026). In a logistic regression model, the odds ratio (OR) for being positive for
the P1A2 polymorphism was significantly reduced by smoking (OR [interquartile range]: 0.26
[0.11 to 0.62]; p  0.0026).
CONCLUSIONS There is a significant reduction in the P1A2 polymorphism in smokers admitted with
non–ST-elevation ACS compared with nonsmokers, which suggests an interaction between
smoking and this polymorphism. (J Am Coll Cardiol 2001;38:1639–43) © 2001 by the
American College of Cardiology
Platelet aggregation with subsequent coronary thrombosis is a
key step in the development of acute coronary syndromes
(ACS) (1–4). Activation of the platelet surface receptor gly-
coprotein IIb/IIIa (GP IIb/IIIa), which binds fibrinogen and
von Willebrand factor, plays an important role in the develop-
ment of such thrombus (5). Several point mutations have been
described for the genes encoding the GP IIb/IIIa receptor,
raising the possibility that they may be implicated in coronary
thrombosis (6). One of these (C1565T) results in a substitu-
tion of proline for leucine at position 33 of the mature GP IIIa
protein, which gives rise to two common alloantigens of GP
IIIa (referred to as P1A or Zw). P1A1 is the more common
allele, while P1A2 is the presumed variant. Following the
original study by Weiss (7) describing an association between
P1A2 and ACS, 23 more studies have been conducted on
Caucasoids of North European extraction and have been
subjected to a recent meta-analysis (8), which suggested that
this polymorphism is not a marker for acute myocardial
infarction (AMI). Some of the discrepancies between the
studies have been attributed to differences in the risk factor
profiles, particularly smoking, between the cases in the various
studies (9). Environmental factors such as smoking are known
to impinge heavily on risk; indeed, the risk of AMI is greatest
in subjects with coagulation disorders who smoke (10). Previ-
ously, we have reported that smoking is predictive of ST-
elevation in patients admitted with AMI (11). Recently, a case
control study of young (45 years) ST-elevation AMI
(STAMI) survivors has reported an association between the
P1A2 polymorphism and STAMI but only in smokers (12).
The interaction was such that smokers with the polymorphism
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had a 13-fold increased risk of AMI compared with nonsokers
without the polymorphism (12). The inference from such an
important interaction in STAMI is that this will be balanced
by proportionally fewer smokers with the P1A2 polymorphism
presenting with milder ACS. In the current study we postu-
lated that, after plaque rupture, the presence of smoking and
the P1A2 polymorphism would produce an exaggerated throm-
botic response favoring STAMI such that there would be a
decrease in the proportion of smokers with the P1A2 polymor-
phism presenting with non–ST-elevation ACS. In order to
investigate this possibility, we have prospectively analyzed an
unselected cohort of patients admitted with non–ST-elevation
ACS and compared the distribution of P1A2 polymorphism in
smokers with nonsmokers.
METHODS
Patients. Consecutive white Caucasoid patients admitted
with non–ST-elevation ACS were recruited if they fulfilled
the criteria for Braunwald class 3B unstable angina (13).
Electrocardiographic changes (ST depression, T-wave in-
version) were not required for inclusion, but patients who
developed Q waves were excluded as were patients with a
myocardial infarction in the previous 21 days. Other exclu-
sion criteria included percutaneous coronary intervention in
the previous six months and cardiac failure (New York
Heart Association grade 3 or 4). The study was approved by
the local ethics committee (East London and City Health
Authority).
Data collection. CLINICAL DATA. Baseline characteristics
including demographic, clinical, smoking status and bio-
chemical data as well as details of the presenting electrocar-
diogram (ECG) were collected prospectively and stored
electronically. Medication being taken before admission was
documented. Current smokers were classed as smokers, while
ex-smokers and nonsmokers were grouped as nonsmokers.
Ex-smokers were defined as patients who had stopped smok-
ing at least one month before the index admission.
BLOOD SAMPLING AND BIOCHEMICAL ANALYSIS. In addi-
tion to samples taken for routine laboratory analysis accord-
ing to hospital protocols, samples were also taken on
admission (before antithrombotic therapy) for troponin I
(Tn I) assay and GP IIIa genotyping and at 12, 24 and 48 h
after admission for Tn I assays only. Whole blood and, after
separation, serum samples were stored at 80°C for later
analysis in batches. Troponin I concentrations were mea-
sured using a one-step sandwich immunoassay with mag-
netic separation (Bayer Immuno 1 Analyser: Bayer Plc.,
Newbury, United Kingdom). The minimum detection limit
was 0.1 g/l. The coefficient of variation was 3.2%
at 2.5 g/l and 10% at 0.3 g/l (manufacturers datasheet).
As recommended by the manufacturers, the cutoff point
used was 0.1 g/l.
DETERMINATION OF GP IIIA GENOTYPES. Genomic DNA
wa extracted from 200 l of whole blood with QIAmp (96)
blood kit (QIAGEN, Crawley, United Kingdom). Glyco-
protein IIIa genotyping was determined as previously de-
scribed. Briefly, a 266 base pair (bp) fragment in exon 2 was
amplified using previously described oligonucleotide prim-
ers (7), with subsequent restriction digest of the polymerase
chain reaction product with Msp 1. The C1565T substitu-
tion results in an extra restriction site with Msp 1 such that
Msp 1 restriction digest of P1A2 individuals yields three
fragments (171 bp, 50 bp and 45 bp) compared with two
fragments for P1A1 individuals (221 bp and 45 bp). These
fragments were then separated on 2.5% agarose gels.
Statistical analysis. Results for continuous variables are
presented as means and SDs. Two sample t tests were used
to compare smokers with nonsmokers. Variables not nor-
mally distributed are presented as medians and interquartile
ranges and compared using the Mann-Whitney U test.
Variables clinically or statistically significant (p  0.05) on
univariate analysis were considered for entry into a multiple
logistic regression model. We then looked at the effect of
adding variables insignificant on univariate analysis to test if
any of these became important after adjustment. Results
from the logistic regression were expressed as the odds of an
individual having one or more copies of the P1A2 allele to a
reference category for categorical variables and as the rela-
tive odds associated with a 1 SD increase in continuous
variables. Pearson chi-square test was used to compare GP
IIIa genotype in smokers and nonsmokers.
RESULTS
Baseline characteristics according to smoking status. A
total of 220 white Caucasoid patients formed the study
group. There were twice as many nonsmokers as smokers
(Table 1). Smokers tended to be younger, but there were no
differences with regard to gender nor in other recognized
clinical risk factors for coronary disease, namely, hyperten-
sion, diabetes and family history. Nonsmokers were more
likely to have had a previous ACS and prior revasculariza-
tion. Although more nonsmokers were taking aspirin on
admission, there were no significant differences in other
antianginal therapies. Nonsmokers had higher serum creat-
inine levels on admission with a tendency to having higher
cholesterol. No significant differences were noted in the
serum glucose on admission. Troponin I was elevated in
similar proportions in smokers and nonsmokers.
Genotypic distributions and allelic frequencies of
P1A1/A2 polymorphism among smokers and nonsmokers.
Examining the study group as a whole, the P1A1/A2 allelic
frequencies were similar to those expected for this popula-
tion (Table 2). Examining the group stratified by smoking
status revealed that the frequency of the P1A2 allele in
nonsmokers was very similar to that expected for North
European Caucasoids. However, a marked reduction in the
Abbreviations and Acronyms
ACS  acute coronary syndromes
AMI  acute myocardial infarction
GP  glycoprotein
STAMI  ST-elevation acute myocardial infarction
Tn I  troponin I
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proportion of smokers positive for this allele was noted
(28.7% vs. 10%; p  0.0026).
Multivariate predictors of subjects positive for the P1A2
polymorphism. Logistic regression analysis showed that
smoking reduced the odds of subjects positive for the P1A2
polymorphism by 74% (p  0.0026) (Table 3). No other
factors including previous cardiac history and treatment
differences predicted P1A2 carriage.
DISCUSSION
Interaction between smoking and the P1A2 polymor-
phism. This study has shown that the frequency of the
P1A2 allele is reduced in smokers as compared with non-
smokers in consecutive white Caucasoid patients admitted
with non–ST-elevation ACS, an observation that has not
previously been reported. Thus, in smokers the odds of
carrying one or more copies of the P1A2 allele was reduced
by 74%. The allelic frequency of this polymorphism in
nonsmokers and for the group overall was equivalent to the
percentage predicted for Caucasoids of North European
extraction from a recent meta-analysis of 5,799 controls (8).
These results support an important interaction between
smoking and the P1A2 polymorphism in ACS.
Determinants of ST elevation. ST-elevation is a marker
of coronary occlusion (14) and is predicted by smoking (11).
The current concept that STAMI and non–ST-elevation
ACS differ in the degree of coronary occlusion that they
produce is now being challenged (15). Recent evidence
would suggest that the spectrum of syndromes that make up
ACS with non–ST-elevation ACS at the milder end of the
spectrum and STAMI and death at the other reflect the
stability of thrombus after plaque rupture (15). Fibrin-rich
thrombus is the hallmark of STAMI, which is slow to lyse
through endogenous fibrinolytic mechanisms and, thus,
presents as AMI. Although fibrin produces a stable clot, it
is most amenable to thrombolytic therapy, resulting in the
excellent response to fibrinolytic therapy (16). In this
paradigm of ACS, the factors determining stability of
thrombus at the time of plaque rupture will be the “hemo-
static milieu” to which the contents of the plaque are
exposed. This “milieu” is itself a mulifactorial phenomenon,
which in the simplest model is due to the interaction
between environmental and genetic factors. Smokers have a
heightened thrombotic response and so are more prone to
STAMI. Paradoxically, therefore, proportionally fewer
Table 1. Baseline Characteristics According to Smoking Status
Smokers†
(n  76)
Nonsmokers
(n  144) p Value
Age 57.6 (10.3) 63.9 (11.2) 0.0001
Male gender 59 (77.6) 104 (72.7) 0.56
Diabetic 10 (13.2) 22 (15.3) 0.56
Hypertensive 26 (34.2) 64 (44.4) 0.14
Family history 40 (52.6) 77 (53.5) 0.91
Cardiac history
Unstable angina 10 (13.2) 35 (24.3) 0.051
Myocardial infarction 23 (30.3) 66 (45.8) 0.026
Revascularization 9 (11.8) 35 (24.3) 0.028
Admission medication
Aspirin 34 (44.7) 87 (60.4) 0.026
Beta-blockers 13 (17.1) 35 (24.3) 0.22
ACE inhibitor 9 (11.8) 26 (18.1) 0.23
Statins 10 (13.2) 24 (16.7) 0.49
Calcium channel
blockers
25 (32.9) 51 (35.4) 0.71
Biochemistry
Cholesterol 5.72 (0.96) 6.01 (1.19) 0.09
Glucose 6.20 (3.85–8.55) 6.40 (4.9–7.9) 0.64
Creatinine 101.1 (23.1) 108.3 (21.9) 0.02
CK peak 166.9 (161.2) 185.4 (219.7) 0.52
Prognostic markers
Tn I  0.1 g/l 50 (65.8) 103 (71.5) 0.38
T-wave inversion 34 (44.7) 73 (50.7) 0.37
ST depression 23 (30.3) 45 (31.3) 0.43
*TnI  0.1 g/l  maximum troponin concentration 0.1 g/l; †current smokers
plus exsmokers who stopped within one month of index admission.
Data are numbers (%) except for age, cholesterol, creatinine, urea and CK peak,
which are mean (SD), and glucose, which is median (interquartile range).
ACE  angiotensin-converting enzyme; CK  creatinine kinase; TnI  troponin I.
Table 2. Genotypic Distributions and Allelic Frequencies of P1A1/A2 Polymorphism Among
Smokers and Nonsmokers
Group
Genotypic Distribution Allelic Frequency
P1A1/A2
n (%)
P1A1/A2 and P1A2/A2
n (%)
% P1A1
Allele
% P1A2
Allele
All patients (n  199) 150 (78.1) 42 (21.9) 88.8 11.2
Nonsmoker (n  122)* 87 (71.3) 35 (28.7) 85.2 14.8
Smoker (n  70)* 63 (90) 7 (10) 94.3 5.7
North European Caucasoid controls†
(n  5799)
4,223 (72.8) 1,577 (27.2) 85.2 14.8
*Pearson 2  9.09, p  0.0026 (smokers compared with nonsmokers); †reference sample (8).
Table 3. Multivariate Predictors of Carriage of the
P1A2 Polymorphism
Odds Ratios
(95% Confidence Interval) p Value
Smoker 0.26 (0.11–0.62) 0.0026
Age 0.98 (0.95–1.01) 0.99
Previous AMI 0.88 (0.23–3.42) 0.85
Previous UA 1.27 (0.36–4.41) 0.71
Aspirin on admission 0.76 (0.35–1.65) 0.49
Cholesterol 1.05 (0.79–1.38) 0.75
Creatinine 1.01 (1.00–1.02) 0.15
Odds ratios represent odds of subjects positive for the P1A2 polymorphism.
AMI  acute myocardial infarction; UA  unstable angina.
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smokers will present with non–ST-elevation ACS as we
have previously demonstrated (17).
If ACS are truly a spectrum determined by the stability
and perhaps extent of clot then any risk factors (environ-
mental or genetic) accumulating at one end of the spectrum
should be balanced by a similar reduction in those same
factors at the opposing end of the spectrum. This seems to
hold true for smoking, and it would also seem to hold true
for the interaction between smoking and the P1A2 polymor-
phism. The results of Ardissino et al. (12), which found an
association between AMI and the P1A2 polymorphism in
young smokers who had survived STAMI, support our
hypothesis and the results of this study. In the aforemen-
tioned study, smokers with AMI were 50% more likely to
have the polymorphism as are nonsmokers with AMI. Our
results indicate that smokers admitted with non–ST-
elevation ACS have a 74% reduction in the odds of carrying
one or more copies of this allele. Combining the results of
these two studies, there is a shortfall of smokers with the
polymorphism, which is presumably accounted for by a
proportion of these patients presenting with sudden death.
This is supported by a Finnish autopsy series that has
reported an excess of the P1A2 polymorphism in sudden
death victims who died of AMI but only if there was
evidence of coronary thrombus (18). They also reported an
association of the P1A2 polymorphism with more vulnerable
plaques but with less severely stenosed coronary arteries. As
many as 75% of sudden death victims may have no evidence
of coronary thrombosis, and, in a proportion of these
patients, death may be secondary to AMI caused by pro-
gressive atherosclerotic narrowing of the culprit vessel
(19,20). In essence, the pathophysiology of AMI may fall
into two distinct bands: those secondary to thrombus on a
vulnerable plaque and those secondary to progressive arterial
narrowing. Furthermore, smoking favors the development
of vulnerable plaques and coronary thrombosis with subse-
quent AMI (21,22).
Previous studies. The inconsistencies of the many studies
that have tested for associations between the P1A2 polymor-
phism and AMI have been attributed to differences in case
and control selections (8). As described in the preceding
text, it can be seen that any association studies testing for
associations between thrombotic genetic markers and coro-
nary syndromes need well-defined study groups, stratified
not only on the basis of risk factors but also on the basis of
the underlying pathophysiology of specific ACS. At present
it is only crudely possible with the use of the 12 lead ECG,
creatinine kinase and troponin levels to subdivide ACS into
three increasingly more severe categories, namely: troponin
negative non–ST-elevation ACS, troponin positive non–
ST-elevation ACS and STAMI. The role of environmental
and genetic factors, although overlapping in these three
categories, may influence the development of these syn-
dromes to different degrees. Thus, an important interaction
in any one of these categories may be overlooked if all
categories are grouped as one. As an example, in the
Physicians Health study (9), which reported no association
between P1A2 and AMI, the prevalence of smoking was very
low (15%) in this presumably health-conscious group. Our
findings, together with those of Ardissino et al. (12), would
suggest that this negative result is entirely consistent with
this group of very few smokers. Furthermore, the low
frequency of the P1A2 polymorphism (21%) for our cohort
as a whole (smokers and nonsmokers) (Table 2) once again
reinforces the need for accurate phenotyping in the defini-
tion of AMI if the subtle molecular, genetic and pathophys-
iologic differences in the spectrum of ACS are to be
resolved.
Study limitations. This is an observational study, and the
influence of the differences between smokers and nonsmok-
ers with regard to age and aspirin on admission as potential
confounding variables should be kept in mind. Nevertheless,
the interaction between smoking and the P1A2 polymor-
phism remains highly significant despite introducing age
and aspirin into the multiple logistic regression model and
suggests that our results are strong.
Conclusions. We have found a lower than expected P1A2
allelic frequency in smokers admitted with non–ST-
elevation ACS. This suggests an important interaction
between smoking and the P1A2 polymorphism in patients
admitted with ACS.
Reprint requests and correspondence: Dr. Khalid Barakat, The
London Chest Hospital, Bonner Road, London E2 9JX, United
Kingdom. E-mail: k.barakat@mds.qmw.ac.uk.
REFERENCES
1. Nairns CR, Topol EJ. Attention shifts to the white clot. Lancet
1997;350 Suppl III:2.
2. Handin RI. Platelets and coronary artery disease. N Engl J Med
1996;334:1126–7.
3. Wu KK. Platelet activation mechanisms and markers in arterial
thrombosis. J Int Med 1996;239:17–34.
4. Platelet activation and arterial thrombosis: report of a meeting of
physicians and scientists, University of Texas Heart Institute, Hous-
ton. Lancet 1994;344:991–5.
5. Nurden AT, Nurden P. A review of the role of platelet membrane
glycoproteins in the platelet vessel wall interaction. Bailliere’s Clin
Haematol 1993;6:653–90.
6. Nurden AT. Polymorphisms of human platelet membrane glycopro-
teins: structure and clinical significance. Thromb Haemost 1995;74:
345–51.
7. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet
glycoprotein receptor as an inherited risk factor for coronary throm-
bosis. N Engl J Med 1996;334:1090–4.
8. Zhu MM, Weedon J, Clarke LT. Meta-analysis of the association of
the P1A1/A2 polymorphism with myocardial infarction. Am J Cardiol
2000;86:1000–4.
9. Ridker PM, Hennekens CH, Schmitz MJ, et al. P1A1/A2 polymor-
phism of platelet glycoprotein IIIa and risks of myocardial infarction,
stroke, and venous thrombosis. Lancet 1997;349:385–8.
10. Bray PF. Integrin polymorphisms as risk factors for thrombosis.
Thromb Haemost 1999;82:337–44.
11. Kennon S, Barakat K, Suliman A, et al. Influence of previous aspirin
treatment and smoking on the electrocardiographic manifestations of
injury in acute myocardial infarction. Heart 2000;84:41–5.
12. Ardissino D, Mannucci PM, Merlini PA, et al. Prothombotic genetic
risk factors in young survivors of myocardial infarction. Blood 1999;
94:46–51.
1642 Barakat et al. JACC Vol. 38, No. 6, 2001
Smoking, GP IIIa P1A2 Polymorphism and ACS November 15, 2001:1639–43
13. A report of the American College of Cardiology and American Heart
Association task force on practice guidelines (committee on the
management of patients with unstable angina). J Am Coll Cardiol
2000;36:970–1063.
14. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary
occlusion during the early hours of transmural myocardial infarction.
N Engl J Med 1980;303:897–902.
15. Rentrop KP. Thrombi in acute coronary syndromes revisited and
revised. Circulation 2000;101:1619–26.
16. Sinapius D. Zur morphologie versschleissender koronarthromben.
Dtsch Med Wochenschr 1972;97:544–51.
17. Kennon S, Suliman A, MacCallum PK, et al. Clinical characteristics
determining the mode of presentation in patients admitted with acute
coronary syndromes. J Am Coll Cardiol 1998;32:2018–22.
18. Mikkelson J, Perola M, Laippala P, et al. Glycoprotein IIIa P1A
polymorphism associates with progression of coronary artery dis-
ease and with myocardial infarction in an autopsy series of middle
aged men who died suddenly. Arterioscler Thromb Vasc Biol
1999;19:2573– 8.
19. Leach IH, Blundell JW, Rowley JM, et al. Acute ischaemic lesions in
death due to ischaemic heart disease: an autopsy study of 333 cases of
out-of-hospital death. Eur Heart J 1995;16:1181–5.
20. Warnes CA, Roberts AW. Sudden coronary death: comparison of
patients with to those without thrombus at necropsy. Am J Cardiol
1984;54:1206–11.
21. Rasheed Q, Nair R, Sheehan H, et al. Correlation of intracoronary
plaque characteristics in atherosclerotic coronary artery disease patients
with clinical variables. Am J Cardiol 1994;73:753–8.
22. Feng D, Lindpainter K, Larson MG, et al. Increased platelet aggre-
gability associated with platelet GPIIIa P1A2 polymorphism: the
Framingham offspring study. Arterioscler Thromb Vasc Biol 1999;19:
1142–7.
1643JACC Vol. 38, No. 6, 2001 Barakat et al.
November 15, 2001:1639–43 Smoking, GP IIIa P1A2 Polymorphism and ACS
